I just wanted to make three key points, really. As has been articulated before, this is a reasonably simple bill which is, in effect, going to provide a remedy in terms of the problem that's been articulated around access to this vaccination. The second element is in regard to, I think, highlighting the complexity in the regulatory burden and the complexity around the Medicines Act; I think that is something that is coming through via this process. I think the learnings that we have taken on board, as we've gone through the COVID response phase, also has highlighted some of the aspects around getting that balance between regulatory oversight and feedback from experts and the ability to move fast and be agile. I think that will no doubt be a key element in terms of any subsequent review that is undertaken in terms of the Government's response to COVID in this country and, hopefully, a process that will be initiated as soon as practicable.